

Revision date: 02-Feb-2000 Version: 1.1 Page 1 of 5

### IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
Ramsgate Road
235 East 42nd Street
Sandwich, Kent
New York, New York 10017
CT13 9NJ
1-212-573-2222
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

Material Name: Lopid tablets (600 mg)

Trade Name:

Synonyms:

Chemical Family:

Intended Use:

Not determined

Not determined

Anti-hyperlipidemic

### 2. COMPOSITION/INFORMATION ON INGREDIENTS

#### **Hazardous**

Ingredient	CAS Number	EU EINECS List	%
Gemfibrozil	25812-30-0	247-280-2	69.8

Additional Information: Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

## 3. HAZARDS IDENTIFICATION

Appearance: solid
Signal Word: CAUTION

Statement of Hazard: May cause eye, skin and respiratory tract irritation May be harmful if swallowed.

**Eye Contact:** May cause eye irritation. **Skin Contact:** May cause skin irritation.

Inhalation: May cause respiratory tract irritation. An Occupational Exposure Limit has been established

for one or more of the ingredients (see Section 8).

Ingestion: May be harmful if swallowed

EU Indication of danger: Harmful

**EU Hazard Symbols:** 

R22 - Harmful if swallowed.

R37/38 - Irritating to respiratory system and skin.

Additional Information: For a more detailed discussion of potential health hazards and toxicity see Section 11.

**Note:**This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the

require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

Material Name: Lopid tablets (600 mg)

Revision date: 02-Feb-2000

Page 2 of 5

Version: 1.1

## 4. FIRST AID MEASURES

Eye Contact: Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get

medical attention.

**Skin Contact:** Remove contaminated clothing and wash the affected area with soap and water. Seek medical

attention if unusual symptoms occur. This material may not be completely removed by conventional laundering. Consult professional laundry service. Do not home launder.

**Ingestion:** In the event of swallowing this material, dilute with large quantities of water or milk. Get

medical attention.

**Inhalation:** Remove to fresh air. If discomfort persists, get medical attention.

#### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: None known or expected.

Fire Fighting Procedures: Wear approved positive pressure, self-contained breathing apparatus and full protective turn

out gear.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

## 6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

**Measures for Cleaning / Collecting:** Wipe up with a damp cloth and place in container for disposal. Clean spill area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

**Additional Consideration for Large** 

Spills:

Contain the source of the spill or leak if it is safe to do so. Spills should be handled by

vacuuming or wet mopping. Clean spill area thoroughly.

Additional Information: Review Sections 3, 8 and 12 before proceeding with clean up.

## 7. HANDLING AND STORAGE

**General Handling:** Avoid contact with eyes. Avoid contact with skin and clothing. Avoid breathing dust.

**Storage Conditions:** Store in a cool, dry place away from direct sunlight.

#### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Gemfibrozil

Pfizer OEL TWA-8 Hr: 1.0 mg/m<sup>3</sup>

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

**Engineering Controls:** Good general ventilation should be sufficient to control airborne levels.

**Personal Protective Equipment:** 

Material Name: Lopid tablets (600 mg)

Revision date: 02-Feb-2000

Page 3 of 5

Version: 1.1

Hands: Chemical protective gloves

Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is

possible.

**Skin:** None required for normal use of this material. Wear protective clothing with long sleeves when

working with large quantities. Wash hands and arms thoroughly after handling this material. None required under normal conditions of use. If the applicable Occupational Exposure Limit

**Respiratory protection:**None required under normal conditions of use. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control

exposures to below the OEL.

### 9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State:TabletColor:WhiteMolecular Formula:MixtureMolecular Weight:Mixture

### 10. STABILITY AND REACTIVITY

**Stability:** Stable under normal conditions of use.

**Conditions to Avoid:** Avoid direct sunlight, conditions that might generate heat, and sources of ignition.

**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers.

**Hazardous Decomposition Products:** None known **Polymerization:** No data available

#### 11. TOXICOLOGICAL INFORMATION

IARC: 3 - Not classifiable as to its carcinogenicity to humans

Acute Toxicity: (Species, Route, End Point, Dose)

#### Gemfibrozil

Mouse Oral LD50 2188 mg/kg
Rat Oral LD50 1831mg/kg
Rat IP LD50 445mg/kg
Mouse IV LD50 > 60mg/kg

Inhalation Acute Toxicity

May cause respiratory tract irritation

Ingestion Acute Toxicity

Eye Irritation / Sensitization

Skin Irritation / Sensitization

Skin Irritation / Sensitization

Skin Irritation / Sensitization

#### Gemfibrozil

2 Week(s) Dog Intravenous 45 mg/kg LOAEL Male reproductive system 2 Week(s) Rat Intravenous 60 mg/kg **NOAEL** No effects at maximum dose Oral LOAEL No effects at maximum dose 13 Week(s) Dog 300 mg/kg **NOAEL** No effects at maximum dose 13 Week(s) Rat Oral 300 mg/kg

#### Gemfibrozil

Reproductive & Fertility-Males Rat Oral 300 mg/kg LOAEL Fertility

Embryo / Fetal Development Rabbit Oral 200 mg/kg NOAEL Not Teratogenic Embryo / Fetal Development Rat Oral 281 mg/kg NOAEL Not Teratogenic Embryo / Fetal Development Rat Oral 300 mg/kg **NOAEL** Not Teratogenic Peri-/Postnatal Development 331 mg/kg LOAEL Rat Oral Fetotoxicity

Reproductive Effects Reproductive toxicity studies are equivocal and inconclusive.

Page 4 of 5

Material Name: Lopid tablets (600 mg)

Revision date: 02-Feb-2000 Version: 1.1

Gemfibrozil

Bacterial Mutagenicity (Ames) Salmonella Negative

In Vitro Sister Chromatid Exchange Chinese Hamster Ovary (CHO) cells Negative

In Vitro Mammalian Cell Mutagenicity Chinese Hamster Ovary (CHO) cells HGPRT Negative

In Vivo Chromosome Aberration Rat Bone Marrow Negative

Mutagenicity This material was non-mutagenic in bacterial and mammalian cells.

Gemfibrozil

52 Week(s) Dog Oral 300 NOAEL Not carcinogenic 52 Week(s) Rat Oral 150 LOAEL Liver, Tumors

Carcinogen Status: Not listed as a carcinogen by IARC, NTP or US OSHA.

Gemfibrozil

IARC: Group 3

Additional Information: Effects reported during consumer use include gastrointestinal disturbances and abdominal

pain.

## 12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this material have not been fully evaluated. Releases to

the environment should be avoided.

Gemfibrozil

Daphnia OECD EC50 48 Hours 21 mg/L Rainbow Trout OECD LC50 96 Hours 22 mg/L Green algae OECD EC50 72 Hours 6.2 mg/L

Gemfibrozil

Nostoc OECD MIC 6 Days 100 mg/L

Aspergillus Niger OECD MIC 72 Hours 1000 mg/L

## 13. DISPOSAL CONSIDERATIONS

**Disposal Procedures:** Observe all local and national regulations when disposing of this material.

### 14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## 15. REGULATORY INFORMATION

EU Labeling: Xn EU Indication of danger: Harmful

Material Name: Lopid tablets (600 mg)

Revision date: 02-Feb-2000

Page 5 of 5

Version: 1.1

**EU Risk Phrases:** 

R22 - Harmful if swallowed.

R37/38 - Irritating to respiratory system and skin.

**EU Safety Phrases:** 

S2 - Keep out of reach of children. S24 - Avoid contact with skin.

S36 - Wear suitable protective clothing.

#### **OSHA Label:**

CAUTION

May cause eye, skin and respiratory tract irritation May be harmful if swallowed.

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision B

Gemfibrozil

California Proposition 65 carcinogen, initial date 12/22/00

female reproductive toxicity, initial date 8/20/99 male reproductive toxicity, initial date 8/20/99

EU EINECS List 247-280-2

# **16. OTHER INFORMATION**

Prepared by: Corporate Occupational Toxicology & Hazard Assessment

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

**End of Safety Data Sheet**